Results of this study may also be indicative of oral orismilast’s ability to contribute to meaningful clinical improvements, investigators noted.
Lutikizumab Demonstrates Positive Results in Phase 2 Trial for Hidradenitis Suppurativa
Higher response rates were observed in patients treated with lutikizumab and the drug advanced to phase 3 clinical trials.
Market Study Reports Secukinumab Emerged as a Leading Treatment for HS
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists.
Investigating Intravenous Ertapenem Therapy for Hidradenitis Suppurativa
IV antibiotics should play a complementary role in the management…